553 billion US dollars RPO provides growth visibility, Bank of America resumes coverage of Oracle Corporation (ORCL.US) and gives a "buy" rating.
Bank of America resumed coverage of IT giant Oracle (ORCL.US) with a "buy" rating and a target price of $200.
Bank of America Corp has resumed coverage of IT giant Oracle Corporation (ORCL.US) with a "buy" rating and a target price of $200.
Analyst Taul Liani stated, "We are resuming coverage of Oracle Corporation with a 'buy' rating and a target price of $200 (approximately 30% upside), reflecting our view on the accelerating demand for artificial intelligence (AI) infrastructure, along with the timing, concentration, and capital requirements balance of Oracle Corporation's transformation process."
Bank of America believes, "Oracle Corporation has significant revenue potential in the future, supported by a remaining performance obligation (RPO) of $553 billion related to long-term AI training and cloud infrastructure commitments. This provides solid visibility for significant growth opportunities, but the company still needs to prove its ability to deliver capacity, convert long-term contracts into revenue, and manage capital-intensive construction processes."
After a detailed analysis, Liani noted that the three key points of contention for Oracle Corporation in the coming years include: the timing for converting its current remaining incomplete orders into revenue (57% of the $553 billion RPO exceeds three years, 22% exceeds five years); customer concentration, especially considering that OpenAI holds a significant portion of its current remaining performance obligations; and the capital intensity of AI construction, as the company's spending has reached levels comparable to those of a hyperscale cloud services provider.
"We believe the company has solid plans in place in these areas, and has discussed both opportunities and related risks," Liani added.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


